|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||120.73 - 121.58|
|52-week range||120.73 - 121.58|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||46.82|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab-rwlc). This announcement underscores Agilent's continuing commitment to the development of IHC-based diagnostics for cancer therapy.
Agilent Technologies Inc. (NYSE: A) has earned the number two position on Barron’s annual list of America’s Most Sustainable Companies. The ranking marks the third straight year Agilent has been included among the top three Most Sustainable Companies. Agilent has also received the number one ranking in the life sciences industry for each of the four years the Barron’s ranking has been compiled.
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. The kit, which marks Agilent’s entrance into SARS-CoV-2 testing in the US, has completed the notification process to FDA in accordance with Section IV.D of FDA’s "Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)". The assay is planned to be registered in other markets in 2021 including Canada, Europe, and selected Asia Pacific and Latin American countries.